Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
#Companion Diagnostics Market Revenue Growth On Track For A 21.1% CAGR Through 2030#_x000D_
The companion diagnostics market has experienced substantial expansion in recent years. This market is projected to grow from $8.69 billion in 2025 to $10.54 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 21.3%. In the past, this growth was primarily driven by the increase in targeted cancer therapies, the expansion of oncology clinical trials, enhanced collaboration between pharmaceutical and diagnostics companies, rising cancer incidence rates, and regulatory approvals for companion tests._x000D_
_x000D_
The companion diagnostics market is poised for substantial growth in the upcoming years. It is forecast to grow to $22.7 billion in 2030 at a compound annual growth rate (CAGR) of 21.1%. This projected expansion during the forecast period is driven by factors such as the increasing demand for tailored treatment selection, growing investments in precision medicine, the broadening of immuno-oncology pipelines, the rising adoption of AI-driven diagnostic interpretation, and a heightened regulatory focus on the co-development of diagnostics and drugs. Significant trends expected during this period include the increased embrace of precision oncology diagnostics, the deeper integration of companion diagnostics into drug development, the expanding application of NGS-based diagnostic platforms, the diversification of biomarker-driven therapies, and a reinforced emphasis on personalized medicine._x000D_
_x000D_
#Get A Free Sample Report With In-Depth Market Insights:#_x000D_
_x000D_
#Companion Diagnostics Market Industry Drivers: What’s Behind The Revenue Growth?#_x000D_
A rising volume of targeted therapies is anticipated to stimulate expansion in the companion diagnostics market. Targeted therapy represents a pharmacological approach focused on specific traits of cancer cells, aiming to suppress disease progression and dissemination. These medications, while circulating systemically, exert a more precise impact compared to chemotherapy, often resulting in fewer side effects. Companion diagnostic testing, utilizing biological markers for targeted cancer treatments, is evolving into a crucial element of individualized cancer management. For example, in February 2024, data from the Personalized Medicine Coalition, a US-based hospital and health care organization, indicated that the FDA approved 16 new personalized treatments for rare disease patients in 2023, an increase from 6 in 2022. Consequently, the rapid increase in targeted therapies fuels the expansion of the companion diagnostics market._x000D_
_x000D_
#Companion Diagnostics Market Segment Landscape: Which Areas Lead Development?#_x000D_
The companion diagnostics market covered in this report is segmented – _x000D_
_x000D_
1) By Product And Service: Assays, Kits And Reagents, Software And Services_x000D_
2) By Technology: Polymerase Chain Reaction, Next-Generation Sequencing, In Situ Hybridization, Immunohistochemistry_x000D_
3) By Indication: Lung Cancer, Breast Cancer, Colorectal Cancer, Leukemia, Melanoma_x000D_
4) By End-User: Pharmaceutical And Biopharmaceutical Companies, Reference Laboratories, Contract Research Organizations_x000D_
_x000D_
Subsegments:_x000D_
1) By Assays: Polymerase Chain Reaction (PCR) Assays, Immunohistochemistry (IHC) Assays, Next-Generation Sequencing (NGS) Assays, In Situ Hybridization (ISH) Assays _x000D_
2) By Kits And Reagents: Diagnostic Kits, Detection Reagents, Control Reagents _x000D_
3) By Software And Services: Data Analysis Software, Interpretation Software, Custom Development Services, Consulting and Support Services_x000D_
_x000D_
#Companion Diagnostics Market Growth Trends: What’s Shaping The Future Outlook?_x000D_
Companies prominent in the companion diagnostics market are forming partnerships to create advanced treatment options aimed at advancing personalized medicine, bettering patient results, and maximizing the efficacy of specific therapies. Such cooperative efforts among these firms will quicken the progress and market launch of companion diagnostics (CDx) for treatments in hematology and oncology. As an illustration, in January 2024, Agilent Technologies, Inc., a US-based provider of laboratory instruments, software, services, and consumables, declared a pact with Incyte, a US-based pharmaceutical company. This arrangement will leverage Agilent’s specialized knowledge and established success in creating companion diagnostics (CDx) to aid in the development and market introduction of Incyte’s range of hematology and oncology products. Through this collaboration, Agilent can broaden its CDx offerings with novel biomarkers, simultaneously benefiting Incyte by accessing Agilent’s proficiency in assay creation, navigating regulatory approvals, and commercialization to facilitate clinical trials and CDx registration across the U.S. and Europe._x000D_
_x000D_
#Companion Diagnostics Market Leading Players And Competitive Positioning#_x000D_
Major companies operating in the companion diagnostics market are F Hoffmann-La Roche Ltd., Agilent Technologies Inc., Qiagen NV, Thermo Fisher Scientific Inc., Abbott Laboratories Inc., Amoy Diagnostics Co. Ltd., Danaher Corporation, Guardant Health Inc., Illumina Inc., Myriad Genetics Inc., Siemens Healthcare GmbH, Almac Group, Caris Life Sciences, Cepheid Inc., Diaceutics plc, Epic Sciences Inc., Foundation Medicine Inc., Genomic Health Inc., Grail Inc., Hologic Inc., HTG Molecular Diagnostics Inc., Inivata Ltd., Invivoscribe Inc., MolecularMD Corporation, Natera Inc., NeoGenomics Laboratories Inc., Personal Genome Diagnostics Inc., Precision Therapeutics Inc., Prometheus Laboratories Inc., Sysmex Corporation, Ventana Medical Systems _x000D_
_x000D_
#View The Full Companion Diagnostics Market Report:#_x000D_
_x000D_
#Companion Diagnostics Market Regional Distribution: Which Areas Power Market Growth?#_x000D_
North America was the largest region in the companion diagnostics market in 2025. The regions covered in the companion diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_
_x000D_
#Reach Out To Our Team:#_x000D_
_x000D_
The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_
Americas: +1 310-496-7795_x000D_
Asia: +44 7882 955267 & +91 8897263534_x000D_
Europe: +44 7882 955267_x000D_
Email us at: marketing@tbrc.info_x000D_
_x000D_
#Follow us on:#_x000D_
_x000D_
LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Wasay has over a decade of experience in market research, data modelling, and analytics, with prior experience at GlobalData and Decision Tree Consulting Services. At The Business Research Company , he leads research operations across syndicated studies, customized consulting engagements, and the Global Market Model platform. His professional experience includes supporting organizations such as Boston Consulting Group, KPMG, and Ernst & Young. Wasay holds a degree in Electronics and Communications Engineering, postgraduate management qualifications from International Management Institute Belgium and Indian School of Business and Entrepreneurship, and completed the Integrated Program in Business Analytics from Indian Institute of Management Indore.